Pitt-Hopkins Syndrome
Trials underway
Dr. Adams and Dr. Krajmalnik-Brown at Arizona State University led a Phase 2, double-blind, placebo-controlled trial assessing the impact of Microbiota Transfer Therapy in patients with Pitt-Hopkins Disease, a genetic disease associated with a severe form of Autism. More details on the study are available here. The study demonstrated microbiota transfer therapy is safe in Pitt-Hopkins patients with improvements in gastrointestinal and Pitt-Hopkins symptoms. The FDA is currently reviewing the treatment protocol for approval. Another trial is in development with a next-generation microbiota therapeutic to allow more patients access who are unable to swallow the standard microbiota therapeutic capsules.
Achieving Cures Together is tax exempt pursuant to IRC Section 501(c)(3). Contributions are deductible to the extent allowed by law.
